Market Overview

UPDATE: Goldman Sachs Raises PT to $32 on Pfizer on Breakup Optionality

Share:
Related PFE
Pfizer's $1.5 Billion Antibiotics Buy: Strategic Long-Term Planning Or Pre-Split Prep?
Risk Arbitrage Trading Strategies
Biotech Funds Are Routine Casualty As Political Rhetoric Ratchets Up (Investor's Business Daily)

Goldman Sachs maintained Pfizer, Inc. (NYSE: PFE) with a Buy rating and raises the price target from $30.00 to $32.00.

Goldman Sachs commented, "PFE reported 4Q12 earnings and gave 2013 financial guidance which included highlighting efforts to optimize both the innovation-driven and value-based businesses as distinct entities. On the conference call, PFE management described the two businesses as already being distinct in developed markets. While the two businesses are intertwined in Emerging Markets – which works well in these high-growth geographies – PFE will consider separating the two business models in these markets as they evolve. This potential move supports our long held view that PFE could unlock substantially greater value by breaking up the business into two separately traded companies."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2016JefferiesMaintainsBuy
Jul 2016JefferiesMaintainsBuy
Jun 2016JefferiesMaintainsBuy

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!